Bleeding Disorder Testing Market
Growth Factors of Bleeding Disorder Testing Market
The bleeding disorder testing market size was valued at USD 88.5 million in 2022, and the market is now projected to grow from USD 94.9 million in 2023 to USD 161.9 million by 2030, exhibiting a CAGR of 7.9% during the forecast period of 2023-2030.
The market for hemophilia A and B treatments and other bleeding disorders was affected by the COVID-19 pandemic because patient visits and diagnostic procedures reduced. There arose a tendency among healthcare providers to concentrate mostly on COVID-19 testing to the neglect of other health threatening diseases. Also, the current-patient fear of infection decimated the number of tests performed for bleeding disorders.
The hike in frequency of diseases such as Hemophilia A, B, and idiopathic thrombocytopenic purpura has put pressure on the number of patients with bleeding disorders. The increase is felt both in developed and emerging parts due to various genetic factors leading to increased patient pools.
The growing incidence due to the genetic factors that include hemophilia A, B and ITP is expanding the patient base. This rise is for both developed as well as the emerging regions. Such several patients speak for the need to improve the diagnostic and therapeutic methods.
Comprehensive Analysis of Bleeding Disorder Testing Market
The bleeding disorder testing market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by product type analysis, by indication analysis, and by end-user analysis. By product type analysis include reagents & consumables and instruments. By indication analysis include hemophilia A, Von Willebrand disease, hemophilia B, idiopathic thrombocytopenic purpura, and others. By end-user analysis include hospitals & clinics, diagnostic centers, and others.
The Europe region lead the bleeding disorder testing market share by benefitting a market size of USD 35.5 million in 2023 due to increasing prevalence of bleeding disorders.
The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, HORIBA Ltd, Sysmex Corporation, Abbott, Thermo Fisher Scientific Inc., Atlas Medical GmbH, HYPHEN BioMed, Precision Biologics these market players provide a level-playing competitive landscape.
In July 2022, HORIBA, Ltd. launched new products in its Yumizen H500 and H550 hematology product family, offering increased benefits, new features, and improved performance.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Forecast Period 2023-2030
Historical Period 2019-2021
Unit Value (USD Million)
Growth Rate CAGR of 7.9% from 2023-2030
Segmentation By Product Type, Indication, End-user, and Region
By Product Type Reagents & Consumables
Instruments
By Indication Hemophilia A
Hemophilia B
Von Willebrand Disease
Idiopathic Thrombocytopenic Purpura
Others
By End-user Hospitals & Clinics
Diagnostic Centers
Others
By Geography North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
Rest of the World
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Bleeding Disorders, by Key Countries, 2022
- 4.2. New Product Launches, By Key Players
- 4.3. Technological Advancements in the Global Bleeding Disorders Testing Market
- 4.4. Impact of COVID-19 on the Market
- 5. Global Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Product Type
- 5.1.1. Reagents & Consumables
- 5.1.2. Instruments
- 5.2. Market Analysis, Insights and Forecast – By Indication
- 5.2.1. Hemophilia A
- 5.2.2. Hemophilia B
- 5.2.3. Von Willebrand Disease
- 5.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast – By End-user
- 5.3.1. Hospitals & Clinics
- 5.3.2. Diagnostic Centers
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
- 6.1. Market Analysis, Insights and Forecast – By Product Type
- 6.1.1. Reagents & Consumables
- 6.1.2. Instruments
- 6.2. Market Analysis, Insights and Forecast – By Indication
- 6.2.1. Hemophilia A
- 6.2.2. Hemophilia B
- 6.2.3. Von Willebrand Disease
- 6.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast – By End-user
- 6.3.1. Hospitals & Clinics
- 6.3.2. Diagnostic Centers
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Product Type
- 7.1.1. Reagents & Consumables
- 7.1.2. Instruments
- 7.2. Market Analysis, Insights and Forecast – By Indication
- 7.2.1. Hemophilia A
- 7.2.2. Hemophilia B
- 7.2.3. Von Willebrand Disease
- 7.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast – By End-user
- 7.3.1. Hospitals & Clinics
- 7.3.2. Diagnostic Centers
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.4.1. U.K
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Product Type
- 8.1.1. Reagents & Consumables
- 8.1.2. Instruments
- 8.2. Market Analysis, Insights and Forecast – By Indication
- 8.2.1. Hemophilia A
- 8.2.2. Hemophilia B
- 8.2.3. Von Willebrand Disease
- 8.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast – By End-user
- 8.3.1. Hospitals & Clinics
- 8.3.2. Diagnostic Centers
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Rest of the World Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Product Type
- 9.1.1. Reagents & Consumables
- 9.1.2. Instruments
- 9.2. Market Analysis, Insights and Forecast – By Indication
- 9.2.1. Hemophilia A
- 9.2.2. Hemophilia B
- 9.2.3. Von Willebrand Disease
- 9.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast – By End-user
- 9.3.1. Hospitals & Clinics
- 9.3.2. Diagnostic Centers
- 9.3.3. Others
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2022)
- 10.2. Company Profiles
- 10.2.1. Siemens Healthcare GmbH
- 10.2.1.1. Overview
- 10.2.1.2. Product
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. financials (Based on Availability)
- 10.2.2. F. Hoffmann-La Roche Ltd.
- 10.2.2.1. Overview
- 10.2.2.2. Product
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. financials (Based on Availability)
- 10.2.3. Thermo Fisher Scientific Inc.
- 10.2.3.1. Overview
- 10.2.3.2. Product
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. financials (Based on Availability)
- 10.2.4. Abbott Laboratories
- 10.2.4.1. Overview
- 10.2.4.2. Product
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. financials (Based on Availability)
- 10.2.5. Atlas Medical GmbH
- 10.2.5.1. Overview
- 10.2.5.2. Product
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. financials (Based on Availability)
- 10.2.6. HORIBA, Ltd.
- 10.2.6.1. Overview
- 10.2.6.2. Product
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. financials (Based on Availability)
- 10.2.7. Sysmex Corporation
- 10.2.7.1. Overview
- 10.2.7.2. Product
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. financials (Based on Availability)
- 10.2.8. HYPHEN BioMed
- 10.2.8.1. Overview
- 10.2.8.2. Product
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. financials (Based on Availability)
- 10.2.9. Precision BioLogic Incorporated
- 10.2.9.1. Overview
- 10.2.9.2. Product
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. financials (Based on Availability)
- 10.2.10. Other Players
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook